外陰膣カンジダ症治療薬市場の規模・シェア・動向分析 (2022-2030年)：薬剤タイプ (クロトリマゾール・フルコナゾール・テルコナゾール)・投与経路・流通チャネル・地域別

世界の外陰膣カンジダ症治療薬の市場規模は、2022年から2030年にかけてCAGR4.39%で推移し、2030年には16億4,000万米ドルの規模に成長すると予測されています。

外陰膣カンジダ症の疾病負担の増加、アンメットニーズに対応する能力を持つ新薬の承認、意識を高めるための政府・非営利組織による取り組みなどの要因が産業の成長を増大させています。

2021年には、処方率が高く、同様の効果を持つ他の薬剤が入手できないことから、フルコナゾールの部門が最大のシェアを示しています。また、投与経路では、アゾールクリームや軟膏などのOTCおよび処方薬の存在により、局所剤の部門が予測期間中に安定したCAGRで成長すると推測されています。

当レポートでは、世界の外陰膣カンジダ症治療薬薬の市場を調査し、市場概要、市場成長への各種影響因子の分析、規制および償還の枠組み、パイプラインの分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 外陰膣カンジダ症治療薬薬市場の可変因子・動向・展望

• 普及・成長の見通しのマッピング
• ユーザー視点分析
• 規制および償還の枠組み
• 市場促進要因の分析
• 市場抑制要因の分析
• COVID-19：影響分析
• SWOT分析
• 産業分析：ポーターの分析
• パイプライン分析

第4章 外陰膣カンジダ症治療薬薬市場：薬剤クラス別

• 動向分析
• クロトリマゾール
• ナイスタチン
• フルコナゾール
• ケトコナゾール
• テルビナフィン
• テルコナゾール
• その他

第5章 外陰膣カンジダ症治療薬薬市場：投与経路別

• 動向分析
• 経口剤
• 静脈内
• 局所剤

第6章 外陰膣カンジダ症治療薬薬市場：流通チャネル別

• 動向分析
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 外陰膣カンジダ症治療薬薬市場：地域別

• 定義・範囲
• 市場シェア分析
• 市場のスナップショット
• 市場規模・予測・収益・動向分析
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 外陰膣カンジダ症治療薬薬市場：競合分析

• 主要参入企業による近年の展開・影響分析
• 企業の分類
• ベンダー情勢
• 主要企業の市場シェア分析
• 公開会社
• 非公開会社
• 企業プロファイル
  • ASTELLAS PHARMA INC.
  • MYCOVIA PHARMACEUTICALS, INC.
  • MYCOVIA PHARMACEUTICALS, INC.
  • SCYNEXIS, INC.
  • GRUPO FERRER INTERNACIONAL, SA
  • PFIZER, INC.
  • BAYER AG
  • CADILA PHARMACEUTICALS
  • BRISTOL-MYERS SQUIBB COMPANY

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviation
• Table 3 List of key distributors
• Table 4 List of other companies
• Table 5 List of key emerging companies/technology disruptors/innovators
• Table 6 Global Vulvovaginal Candidiasis Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 7 Global Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 8 Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 9 Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 North America Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 11 North America Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 12 North America Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 13 North America Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 14 U.S. Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 15 U.S. Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 16 U.S. Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 18 Canada Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 19 Canada Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 Europe Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 21 Europe Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 22 Europe Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 23 Europe Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 24 U.K. Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 25 U.K. Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 26 U.K. Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 27 Germany Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 28 Germany Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 29 Germany Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 30 France Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 31 France Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 32 France Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 Spain Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 34 Spain Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 35 Spain Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 36 Italy Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 37 Italy Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 38 Italy Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 39 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Japan Vulvovaginal Candidiasis Treatment Market, By Drug Class Type, 2018 - 2030 (USD Million)
• Table 44 Japan Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 45 Japan Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 China Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 47 China Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 48 China Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 India Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 50 India Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 India Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 52 Australia Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 53 Australia Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 54 Australia Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 55 South Korea Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 56 South Korea Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 57 South Korea Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Latin America Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 59 Latin America Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 60 Latin America Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Latin America Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Brazil Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 63 Brazil Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 64 Brazil Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Mexico Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 66 Mexico Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 67 Mexico Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Argentina Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 69 Argentina Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 70 Argentina Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 71 MEA Vulvovaginal Candidiasis Treatment Market, By Country, 2018 - 2030 (USD Million)
• Table 72 MEA Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 73 MEA Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 74 MEA Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 South Africa Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 76 South Africa Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 77 South Africa Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 80 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 81 UAE Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 82 UAE Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 83 UAE Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million

List of Figures

• Fig. 1 Vulvovaginal candidiasis treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market outlook (2021)
• Fig. 10 Penetration and growth prospect mapping
• Fig. 11 User perspective analysis
• Fig. 12 Vulvovaginal candidiasis treatment market driver impact
• Fig. 11 Prevalence of VVC (in 2021)
• Fig. 12 Vulvovaginal candidiasis treatment market restraint impact
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Vulvovaginal candidiasis treatment drug class outlook: Key takeaways
• Fig. 16 Vulvovaginal candidiasis treatment market: Drug class movement analysis
• Fig. 17 Clotrimazole market, 2018 - 2030 (USD million)
• Fig. 18 Nystatin market, 2018 - 2030 (USD million)
• Fig. 19 Fluconazole market, 2018 - 2030 (USD million)
• Fig. 20 Ketoconazole market, 2018 - 2030 (USD million)
• Fig. 21 Terbinafine market, 2018 - 2030 (USD million)
• Fig. 22 Terconazole market, 2018 - 2030 (USD million)
• Fig. 23 Others market, 2018 - 2030 (USD million)
• Fig. 24 Vulvovaginal candidiasis treatment market route of administration outlook: Key takeaways
• Fig. 25 Vulvovaginal candidiasis treatment: Route of administration movement analysis
• Fig. 26 Oral market, 2018 - 2030 (USD million)
• Fig. 27 Intravenous market, 2018 - 2030 (USD million)
• Fig. 28 Topical market, 2018 - 2030 (USD million)
• Fig. 29 Vulvovaginal candidiasis treatment distribution channel outlook: Key takeaways
• Fig. 30 Vulvovaginal candidiasis treatment market: Distribution channel movement analysis
• Fig. 31 Hospital pharmacy market, 2018 - 2030 (USD million)
• Fig. 32 Retail pharmacy market, 2018 - 2030 (USD million)
• Fig. 33 Online pharmacy market, 2018 - 2030 (USD million)
• Fig. 34 Regional outlook, 2021 & 2030
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 North America
• Fig. 37 North America vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 38 U.S.
• Fig. 39 U.S. vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 40 Canada
• Fig. 41 Canada vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 42 Europe
• Fig. 43 Europe vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 44 U.K.
• Fig. 45 U.K. vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 46 Germany
• Fig. 47 Germany vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 48 France
• Fig. 49 France vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 50 Spain
• Fig. 51 Spain vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 52 Italy
• Fig. 53 Italy vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 54 Asia Pacific
• Fig. 55 Asia Pacific vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 56 Japan
• Fig. 57 Japan vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 58 China
• Fig. 59 China vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 60 India
• Fig. 61 India vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 62 Australia
• Fig. 63 Australia vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 64 South Korea
• Fig. 65 South Korea vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 66 Latin America
• Fig. 67 Latin America vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 68 Brazil
• Fig. 69 Brazil vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 70 Mexico
• Fig. 71 Mexico vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 72 Argentina
• Fig. 73 Argentina vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 74 Middle East & Africa
• Fig. 75 Middle East & Africa vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 76 South Africa
• Fig. 77 South Africa vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 78 Saudi Arabia
• Fig. 79 Saudi Arabia vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 80 UAE
• Fig. 81 UAE vulvovaginal candidiasis treatment market, 2018 - 2030 (USD Million)
• Fig. 82 Heat map analysis
• Fig. 83 Company market share analysis (2021)
• Fig. 84 Company market position analysis (2021)
• Fig. 85 Company market position analysis (2021)
• Fig. 86 Market differentiators
• Fig. 87 Regional Network Map

Vulvovaginal Candidiasis Treatment Market Growth & Trends:

The global vulvovaginal candidiasis treatment market size is expected to reach USD 1.64 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.39% from 2022 to 2030. The increasing disease burden of VVC, approval of novel drugs with the ability to address the unmet needs, and efforts by government & non-profit organizations to increase awareness are among the key factors augmenting the industry growth. According to the NCBI article, globally, around 75% of women suffer from this disease once in their life.Vulvovaginal candidiasis is the second most common infection in women, affecting around 138 million women globally.

About 10-20% of women report complicated disease conditions, which are increasing annually. Moreover, the NCBI article reports an upsurge in recurrent infection incidences. Thus, the rising prevalence of the disease is boosting the treatment demand, thereby driving industry growth.Azoles, such as fluconazole, are indicated as the first line of treatment and held a significant share of the market, however, in recent years, there has been a surge in azole resistance cases, which led to rising in recurring disease cases. However, novel drugs, such as VIVJOA and BREXAFEMME, are effectiveagainst recurring VVC. In addition, the presence of over-the-counter intravaginal agents, which enables easy patient treatment access, supports the market growth.

This includes products, such as miconazole cream, clotrimazole cream, and tioconazole ointment. They are indicated to treat mild to moderate conditions and are used as maintenance therapy. The industry is saturated with generic products, which could slow down growth. However, key players, such as Mycovia Pharmaceuticals and SCYNEXIS, Inc., are engaged in strategic initiatives like new product development and launches, which are anticipated to propel the market growth over the forecast period. For instance, in July 2022, Mycovia Pharmaceuticals launched VIVJOA for recurrent VVC. The company has already received VIVJOA approval in Asian, European, and Latin American countries. In September 2021, SCYNEXIS, Inc. launched BREXAFEMME in the U.S., the first oral non-azole therapeutic indicated for VVC.

Vulvovaginal Candidiasis Treatment Market Report Highlights:

• In 2021, the fluconazole segment accounted for the largest share owing to its high prescription rate and the non-availability of other drugs with similar efficacy

• The topical segment is estimated to grow at a steady CAGR during the forecast period due to the presence of OTC and prescription formulations, such as azole creams and ointments

• Based on distribution channel, the retail pharmacy segment dominated the industry in 2021 due to the ease of availability and the presence of OTCs drugs

• Asia Pacific is anticipated to experience the fastest CAGR over the forecast period due to increased awareness among the population, rise in disposable income, and high prevalence of VVC in developing countries

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List Of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Outlook

Chapter 3 Vulvovaginal Candidiasis Treatment market Variables, Trends, and Scope

• 3.1 Penetration and Growth Prospect Mapping
• 3.2 User Perspective Analysis
• 3.3 Regulatory and Reimbursement Framework
• 3.4 Market Driver analysis
  • 3.4.1 Rising Prevalence Of The Disease
  • 3.4.2 Strong Emerging Pipeline
• 3.5 Market Restraint Analysis
  • 3.5.1 Availability Of Generic Drugs In Market
• 3.6 Covid-19 Impact Analysis
• 3.7 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• 3.8 Industry Analysis - Porter's
• 3.9 Pipeline Analysis

Chapter 4 Vulvovaginal Candidiasis Treatment market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

• 4.1 Vulvovaginal Candidiasis Treatment market: Drug Class Movement Analysis
• 4.2 Clotrimazole
  • 4.2.1 Clotrimazole Market, 2018 - 2030 (USD Million)
• 4.3 Nystatin
  • 4.3.1 Nystatin Market, 2018 - 2030 (USD Million)
• 4.4 Fluconazole
  • 4.4.1 Fluconazole Market, 2018 - 2030 (USD Million)
• 4.5 Ketoconazole
  • 4.5.1 Ketoconazole Market, 2018 - 2030 (USD Million)
• 4.6 Terbinafine
  • 4.6.1 Terbinafine Market, 2018 - 2030 (USD Million)
• 4.7 Terconazole
  • 4.7.1 Terconazole Market, 2018 - 2030 (USD Million)
• 4.8 Others
  • 4.8.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Vulvovaginal Candidiasis Treatment market: Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

• 5.1 Vulvovaginal Candidiasis Treatment market: Route of Administration Movement Analysis
• 5.2 Oral
  • 5.2.1 Oral Market, 2018 - 2030 (USD Million)
• 5.3 Intravenous
  • 5.3.1 Intravenous Market, 2018 - 2030 (USD Million)
• 5.4 Topical
  • 5.4.1 Topical Market, 2018 - 2030 (USD Million)

Chapter 6 Vulvovaginal Candidiasis Treatment market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Vulvovaginal Candidiasis Treatment market: Distribution Channel Movement Analysis
• 6.2 Hospital Pharmacy
  • 6.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• 6.3 Retail Pharmacy
  • 6.3.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 6.4 Online Pharmacy
  • 6.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7 Vulvovaginal Candidiasis Treatment market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2021 & 2030
• 7.3 Regional Market Snapshot
• 7.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
  • 7.4.1 North America
    • 7.4.1.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.4.1.2 U.S.
    • 7.4.1.2.1 U.S. Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.1.3 Canada
    • 7.4.1.3.1 Canada Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.2 Europe
    • 7.4.2.1 Europe Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2.2 U.K.
    • 7.4.2.2.1 U.K. Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2.3 Germany
    • 7.4.2.3.1 Germany Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2.4 France
    • 7.4.2.4.1 France Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2.5 Spain
    • 7.4.2.5.1 Spain Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2.6 Italy
    • 7.4.2.6.1 Italy Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.3 Asia Pacific
    • 7.4.3.1 Asia Pacific Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3.2 Japan
    • 7.4.3.2.1 Japan Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3.3 China
    • 7.4.3.3.1 China Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3.4 India
    • 7.4.3.4.1 India Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3.5 Australia
    • 7.4.3.5.1 Australia Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.3.6 South Korea
    • 7.4.3.6.1 South Korea Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.4 Latin America
    • 7.4.4.1 Latin America Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4.2 Brazil
    • 7.4.4.2.1 Brazil Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4.3 Mexico
    • 7.4.4.3.1 Mexico Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.4.4 Argentina
    • 7.4.4.4.1 Argentina Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
  • 7.4.5 Middle East & Africa
    • 7.4.5.1 Middle East & Africa Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5.2 South Africa
    • 7.4.5.2.1 South Africa Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5.3 Saudi Arabia
    • 7.4.5.3.1 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.5.4 UAE
    • 7.4.5.4.1 UAE Vulvovaginal Candidiasis Treatment Market, 2018 - 2030 (USD Million)

Chapter 8 Vulvovaginal Candidiasis Treatment market: Competitive Analysis

• 8.1 Recent Developments and Impact Analysis, by Key Market Participants
  • 8.1.1 New Product Launches
  • 8.1.2 Mergers And Acquisitions
  • 8.1.3 Partnerships And Strategic Collaboration
  • 8.1.4 Conferences And Campaigns
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market Leaders
  • 8.2.3 Heat Map Analysis
• 8.3 Vendor Landscape
  • 8.3.1 List Of Key Distributors And Channel Partners
  • 8.3.2 Key Customers
• 8.4 Key Company Market Share Analysis, 2021
• 8.5 Public Companies
  • 8.5.1 Company Market Position Analysis
  • 8.5.2 Competitive Dashboard Analysis
    • 8.5.2.1 Market Differentiators
• 8.6 Private Companies
  • 8.6.1 List Of Key Emerging Companies
  • 8.6.2 Regional Network Map
• 8.7 Company Profiles
  • 8.7.1 ASTELLAS PHARMA INC.
    • 8.7.1.1 Company Overview
    • 8.7.1.2 Financial Performance
    • 8.7.1.3 Product benchmarking
    • 8.7.1.4 Strategic initiatives
  • 8.7.2 MYCOVIA PHARMACEUTICALS, INC.
    • 8.7.2.1 Company overview
    • 8.7.2.2 Financial Performance
    • 8.7.2.3 Product benchmarking
    • 8.7.2.4 Strategic initiatives
  • 8.7.3 MYCOVIA PHARMACEUTICALS, INC.
    • 8.7.3.1 Company Overview
    • 8.7.3.2 Financial Performance
    • 8.7.3.3 Product Benchmarking
    • 8.7.3.4 Strategic Initiatives
  • 8.7.4 SCYNEXIS, INC.
    • 8.7.4.1 Company Overview
    • 8.7.4.2 Financial Performance
    • 8.7.4.3 Product Benchmarking
    • 8.7.4.4 Strategic Initiatives
  • 8.7.5 GRUPO FERRER INTERNACIONAL, S.A.
    • 8.7.5.1 Company Overview
    • 8.7.5.2 Financial Performance
    • 8.7.5.3 Product Benchmarking
    • 8.7.5.4 Strategic Initiatives
  • 8.7.6 PFIZER, INC.
    • 8.7.6.1 Company Overview
    • 8.7.6.2 Financial Performance
    • 8.7.6.3 Product Benchmarking
    • 8.7.6.4 Strategic Initiatives
  • 8.7.7 BAYER AG
    • 8.7.7.1 Company Overview
    • 8.7.7.2 Financial Performance
    • 8.7.7.3 Product Benchmarking
    • 8.7.7.4 Strategic Initiatives
  • 8.7.8 CADILA PHARMACEUTICALS
    • 8.7.8.1 Company Overview
    • 8.7.8.2 Financial Performance
    • 8.7.8.3 Product Benchmarking
    • 8.7.8.4 Strategic Initiatives
  • 8.7.9 BRISTOL-MYERS SQUIBB COMPANY
    • 8.7.9.1 Company overview
    • 8.7.9.2 Financial Performance
    • 8.7.9.3 Product benchmarking
    • 8.7.9.4 Strategic initiatives